Faron registers new shares as major equity offering nears completion

An update from Faron Pharmaceuticals Oy ( (GB:FARN) ) is now available.

Faron Pharmaceuticals has registered 38,055,229 new shares with the Finnish Trade Register, allocated to cornerstone investors and guarantors as part of an 80,158,126-share offering. Following this registration, the company now has 157,527,889 registered shares, of which 41,743,928 are held in treasury, giving a current total of 115,783,961 voting rights.

Once all offer shares are registered and settled, Faron’s total share count will rise to 199,472,660, with treasury shares reduced to 3,530,573 and voting rights increasing to 195,942,087. The new shares are being admitted to trading on Nasdaq First North Growth Market Finland and London’s AIM, with trading in the new and remaining offer shares expected to commence around 14–15 April 2026, significantly expanding the company’s free float and investor base.

More about Faron Pharmaceuticals Oy

Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company listed on AIM in London and Nasdaq First North in Helsinki. The company focuses on developing novel immunotherapies to tackle cancers, including its wholly owned investigational drug bexmarilimab, which targets the Clever-1 receptor on macrophages to reprogram the tumor microenvironment and enhance responses to standard treatments.

For detailed information about FARN stock, go to TipRanks’ Stock Analysis page.